Raymond Wadlow

6.9k total citations
36 papers, 944 citations indexed

About

Raymond Wadlow is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Raymond Wadlow has authored 36 papers receiving a total of 944 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 12 papers in Cancer Research and 9 papers in Molecular Biology. Recurrent topics in Raymond Wadlow's work include Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). Raymond Wadlow is often cited by papers focused on Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). Raymond Wadlow collaborates with scholars based in United States, India and Germany. Raymond Wadlow's co-authors include Sridhar Ramaswamy, David P. Ryan, Lawrence S. Blaszkowsky, Andrew X. Zhu, D. Gary Gilliland, Ian F. Dunn, Anna C. Schinzel, Konstanze Döhner, Stefan Fröhling and Jesse S. Boehm and has published in prestigious journals such as Cell, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Raymond Wadlow

31 papers receiving 922 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raymond Wadlow United States 14 485 484 196 179 138 36 944
Sachiyo Mimaki Japan 17 528 1.1× 568 1.2× 260 1.3× 385 2.2× 184 1.3× 36 1.1k
Shane R. Stecklein United States 16 471 1.0× 374 0.8× 356 1.8× 130 0.7× 96 0.7× 52 934
Yunxiao Meng China 17 261 0.5× 510 1.1× 339 1.7× 97 0.5× 73 0.5× 32 909
Hideaki Mitsui Japan 18 320 0.7× 393 0.8× 206 1.1× 290 1.6× 79 0.6× 47 863
Carla Kurkjian United States 17 302 0.6× 481 1.0× 130 0.7× 157 0.9× 58 0.4× 41 830
Tessa Y. S. Le Large Netherlands 15 407 0.8× 226 0.5× 210 1.1× 116 0.6× 122 0.9× 28 656
Michel Maira Switzerland 8 269 0.6× 629 1.3× 129 0.7× 180 1.0× 61 0.4× 12 837
Michael E. Menefee United States 15 610 1.3× 484 1.0× 181 0.9× 209 1.2× 59 0.4× 45 1.3k
Oriol Arpí Spain 15 376 0.8× 359 0.7× 149 0.8× 126 0.7× 74 0.5× 24 710
Marianna Scrima Italy 17 237 0.5× 640 1.3× 302 1.5× 182 1.0× 82 0.6× 30 890

Countries citing papers authored by Raymond Wadlow

Since Specialization
Citations

This map shows the geographic impact of Raymond Wadlow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond Wadlow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond Wadlow more than expected).

Fields of papers citing papers by Raymond Wadlow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond Wadlow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond Wadlow. The network helps show where Raymond Wadlow may publish in the future.

Co-authorship network of co-authors of Raymond Wadlow

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond Wadlow. A scholar is included among the top collaborators of Raymond Wadlow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond Wadlow. Raymond Wadlow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Christenson, Eric S., Daruka Mahadevan, Syed Mohammad Ali Kazmi, et al.. (2024). A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 2538–2538. 2 indexed citations
3.
Lentz, Robert W., Patrick J. Blatchford, Junxiao Hu, et al.. (2024). Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).. Journal of Clinical Oncology. 42(16_suppl). 3530–3530. 1 indexed citations
4.
Cannon, Timothy Lewis, Ethan S. Sokol, Raymond Wadlow, et al.. (2022). Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. Cancer Treatment and Research Communications. 32. 100569–100569. 4 indexed citations
5.
Roth, Marc, Dana B. Cardin, Erkut Borazanci, et al.. (2020). A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma. The Oncologist. 25(10). e1446–e1450. 27 indexed citations
6.
Goyal, Lipika, Surendra Pal Chaudhary, Eunice L. Kwak, et al.. (2020). A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. Investigational New Drugs. 38(5). 1533–1539. 17 indexed citations
7.
Salgia, Nicholas, Sumanta K. Pal, Vincent Chung, et al.. (2019). Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with advanced urothelial cancer: Preliminary results of a phase IIa study.. Journal of Clinical Oncology. 37(7_suppl). 455–455.
8.
Shields, Anthony F., et al.. (2017). Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer.. PubMed. 31(4). 301–12. 3 indexed citations
9.
Bullock, Andrea J., Keith Stuart, Susanna Jacobus, et al.. (2017). Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology. 8(6). 945–952. 10 indexed citations
10.
11.
Goyal, Lipika, Raymond Wadlow, Lawrence S. Blaszkowsky, et al.. (2014). A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Investigational New Drugs. 33(1). 128–137. 42 indexed citations
12.
Russo, Andrea, Darrell R. Borger, Jackie Szymonifka, et al.. (2014). Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 120(10). 1482–1490. 62 indexed citations
13.
Chan, Jennifer A., Lawrence S. Blaszkowsky, Keith Stuart, et al.. (2013). A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer. 119(17). 3212–3218. 64 indexed citations
14.
Arvold, Nils D., Christopher G. Willett, Carlos Fernández‐del Castillo, et al.. (2012). Pancreatic Neuroendocrine Tumors With Involved Surgical Margins: Prognostic Factors and the Role of Adjuvant Radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 83(3). e337–e343. 20 indexed citations
15.
Childs, Stephanie, Harvey J. Mamon, Jennifer Y. Wo, et al.. (2012). Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival.. Journal of Clinical Oncology. 30(4_suppl). 301–301.
16.
Arvold, Nils D., David P. Ryan, Andrzej Niemierko, et al.. (2011). Long‐term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 118(12). 3026–3035. 57 indexed citations
17.
Wadlow, Raymond, Aram F. Hezel, Thomas A. Abrams, et al.. (2011). Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab. The Oncologist. 17(1). 14–e34. 67 indexed citations
18.
Scholl, Claudia, Stefan Fröhling, Ian F. Dunn, et al.. (2009). Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells. Cell. 137(5). 821–834. 416 indexed citations
19.
Wadlow, Raymond, Ben S. Wittner, Rabi Upadhyay, et al.. (2009). Systems-Level Modeling of Cancer-Fibroblast Interaction. PLoS ONE. 4(9). e6888–e6888. 22 indexed citations
20.
Wadlow, Raymond & David Porter. (2002). Umbilical cord blood transplantation: Where do we stand?. Biology of Blood and Marrow Transplantation. 8(12). 637–647. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sachiyo Mimaki Breakdown of academic impact, for papers by Shane R. Stecklein Breakdown of academic impact, for papers by Yunxiao Meng Breakdown of academic impact, for papers by Hideaki Mitsui Breakdown of academic impact, for papers by Carla Kurkjian Breakdown of academic impact, for papers by Tessa Y. S. Le Large Breakdown of academic impact, for papers by Michel Maira Breakdown of academic impact, for papers by Michael E. Menefee Breakdown of academic impact, for papers by Oriol Arpí Breakdown of academic impact, for papers by Marianna Scrima
Rankless by CCL
2026